Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 6/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 9/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20324650 | 0.93 | POLB (0.47) | POLBPNPNT5ETGM2P2RY2 | |
| SCHEMBL20327594 | 0.90 | POLB (0.43) | POLBPNPNT5ETGM2P2RY2 | |
| SCHEMBL20324574 | 0.90 | POLB (0.43) | POLBPNPNT5ETGM2P2RY2 | |
| SCHEMBL22399465 | 0.83 | PNP (0.44) | POLBPNP | |
| SCHEMBL20325289 | 0.83 | POLB (0.45) | POLB | |
| SCHEMBL20325346 | 0.83 | POLB (0.64) | POLBNT5ETGM2P2RY2P2RY4 | |
| SCHEMBL20325348 | 0.83 | POLB (0.64) | POLBNT5ETGM2P2RY2P2RY4 | |
| SCHEMBL20324724 | 0.82 | PNP (0.45) | POLBPNPNT5ETGM2FUT5 | |
| SCHEMBL20327593 | 0.81 | POLB (0.35) | POLBNT5ETGM2P2RY2P2RY4 | |
| SCHEMBL20324564 | 0.80 | P2RY2 (0.38) | POLBNT5ETGM2P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |